Jack Nielsen
Managing Partner at Vivo Capital
Jack Nielsen
Managing Partner at Vivo Capital
Palo Alto, California
Overview
Work Experience
Managing Partner
2017 - Current
Consultant
2017 - 2017
Vivo is a global investment firm focused on healthcare with approximately $5.8 billion in AUM
Board Member
2021
Ocelot Bio brings new treatment options to patients with severe liver disease.
Raised $39,000,000.00 from Venrock, RA Capital Management and Vivo Capital.
Board Member
2021
IO Biotech went public on Nasdaq in November 2021 under Ticker IOBT
Board Member
2020
Instil Bio went public on Nasdaq in March 2021 under Ticker TIL
Instil Bio is a biotechnology company that develops cell therapies for solid tumor cures.
Raised $200,200,000.00 from HBM Healthcare Investments.
Board Member
2020
ALX Oncology went public on Nasdaq in July 2020 under Ticker ALXO
ALX Oncology is a preclinical stage biotechnology company developing innovative immuno-oncology therapies for cancer.
Raised $329,200,000.00 from Silicon Valley Bank and Oxford Finance LLC.
Chairman / Lead Director
2018
Aligos went public on Nasdaq in October 2020 under Ticker ALGS
Aligos Therapeutics is discovering and developing new classes of molecules that interact directly with disease-causing modalities.
Raised $400,600,000.00 from Deep Track Capital, EcoR1 Capital, Armistice Capital, Lawrence Blatt and Roche Venture Fund.
Board Member
2017
Harmony Biosciences went public on NASDAQ August 2020 under ticker HRMY
Lead Director - Board Member
2006 - 2022
Reata went public on Nasdaq in May 2016 under Ticker RETA. Acquired by Biogen in 2023 for $7.3 BUSD
Reata Pharmaceuticals is a biopharmaceutical company that develops drugs for cancer, inflammation, and neurodegenerative diseases.
Raised $2,006,204,729.00 from Blackstone Life Sciences.
Board Member
2019 - 2022
LumiThera acquired the Maculogix in 2022
Board Observer
2018 - 2020
Passage Bio raised 216 MUSD in an IPO on NASDAQ under ticker PASG
Passage Bio is a fully integrated gene therapy company developing therapies for the treatment of monogenic central nervous system diseases.
Raised $379,500,000.00 from Lilly Asia Ventures, Highline Capital Management, Sphera Funds Management, Versant Ventures, New Leaf Venture Partners, Boxer Capital, Logos Capital, Access Biotechnology, OrbiMed and Frazier Healthcare Partners.